entri
envelop
virus
host
cell
involv
sever
success
step
one
amen
therapeut
intervent
entri
inhibitor
act
target
viral
andor
cellular
compon
either
inhibit
proteinprotein
interact
within
viral
envelop
protein
viral
protein
host
cell
receptor
inhibit
proteinlipid
interact
interestingli
inhibitor
concentr
intoonto
membran
order
target
protein
involv
entri
process
arbidol
peptid
inhibitor
human
immunodefici
viru
hiv
could
allow
use
dose
compat
therapeut
requir
efficaci
drug
valid
entri
point
intervent
viral
life
cycl
strategi
base
upon
small
molecul
antivir
agent
peptid
protein
nucleic
acid
would
like
prove
effici
multidrug
combin
order
inhibit
sever
step
viru
life
cycl
prevent
diseas
progress
therapeut
inhibit
viru
infect
could
involv
sever
strategi
target
variou
step
viru
life
cycl
cell
entri
viru
replic
assembl
releas
newlyform
virion
review
focu
strategi
aim
inhibit
cell
entri
step
envelop
open
access
virus
major
effort
invest
find
novel
specif
less
toxic
antivir
strategi
target
entri
envelop
virus
attract
strategi
therapeut
intervent
sinc
site
action
inhibitor
like
extracellular
therefor
rel
access
could
also
limit
cell
toxic
moreov
one
could
expect
benefici
effect
upstream
damag
would
occur
cell
later
viral
life
cycl
penetr
envelop
viru
target
cell
first
step
viral
replic
cycl
stage
could
constitut
potenti
target
inhibitor
figur
phindepend
cell
entri
envelop
viru
blue
viru
attach
receptor
induc
chang
viral
envelop
glycoprotein
mediat
fusion
plasma
membran
subsequ
genom
releas
neutral
ph
phdepend
cell
entri
envelop
viru
orang
attach
receptor
viru
reach
endosom
compart
acid
ph
induc
conform
rearrang
viral
envelop
glycoprotein
mediat
membran
fusion
lead
genom
releas
acid
ph
hcv
cell
entri
red
initi
attach
cell
factor
includ
ldlr
gag
hcv
bind
specif
receptor
srbi
occludin
mediat
viru
intern
via
clathrindepend
endocytosi
acid
ph
earli
endosom
may
induc
conform
rearrang
viral
envelop
glycoprotein
lead
membran
fusion
genom
releas
cytosol
schemat
enter
cell
envelop
virus
first
attach
one
sever
plasma
membran
receptor
via
envelop
protein
case
phindepend
entri
initi
bind
lead
conform
chang
envelop
fusion
protein
eventu
expos
fusion
peptid
insert
peptid
plasma
membran
allow
fusion
viral
plasma
membran
releas
viru
genom
cytoplasm
membran
fusion
virus
display
phdepend
entri
occur
within
acid
environ
endosom
compart
ph
induc
conform
chang
fusion
protein
lead
exposur
fusion
peptid
stage
potenti
amen
therapeut
intervent
review
therefor
discuss
variou
possibl
target
context
recent
develop
antivir
molecul
knowledg
understand
antivir
strategi
studi
appli
envelop
virus
could
lead
develop
new
inhibitor
viral
envelop
protein
two
function
specif
attach
cell
membran
fusion
two
function
could
involv
one
protein
viral
fusion
protein
defin
three
class
mainli
depend
structur
featur
fusion
protein
three
class
display
differ
architectur
adopt
fusion
similar
overal
hairpin
conform
figur
howev
mani
viru
famili
structur
inform
still
miss
identifi
classifi
membran
fusion
protein
class
protein
mostli
contain
alphahel
structur
hydrophob
fusion
peptid
locat
nterminu
buri
within
protein
core
protein
associ
homotrim
project
vertic
viral
membran
group
includ
protein
sever
viral
famili
retrovirida
human
immunodefici
viru
hiv
orthomyxovirida
influenza
viru
ha
protein
paramyxovirida
respiratori
syncyti
viru
rsv
f
protein
filovirida
ebola
protein
coronavirida
coronaviru
protein
prefus
complex
class
ii
fusion
protein
conform
present
surfac
infecti
viral
particl
influenza
viru
hemagglutinin
complex
organ
trimer
receptorbind
subunit
shown
white
membranefus
subunit
colour
blue
red
fusion
peptid
yellow
residu
buri
trimer
center
arrow
b
alphaviru
semliki
forest
viru
prefus
complex
trimer
membran
fusion
subunit
drawn
tube
colour
domain
receptorbind
subunit
display
spherefil
model
colour
grey
base
substract
densiti
cryoelectron
microscopi
reconstruct
viru
orang
fusion
peptid
arrow
buri
interfac
c
prefus
complex
e
tickborn
enceph
flaviviru
fusion
peptid
buri
e
homodim
interfac
arrow
three
panel
drawn
scale
viral
membran
would
tangenti
horizont
plane
draw
b
postfus
conform
class
ii
fusion
protein
demonstr
suggest
membran
interact
protein
final
fuse
membran
pictur
cartoon
form
class
protein
ha
influenza
viru
left
drawn
ntermin
half
hairpin
blue
ctermin
part
red
miss
fusion
peptid
transmembran
domain
indic
one
three
trimer
subunit
appear
blue
red
star
respect
membraneproxim
extend
ctermin
leash
interact
central
coiledcoil
domain
ha
class
ii
protein
elong
red
star
indic
predict
locat
tm
segment
red
arrow
point
c
terminu
one
subunit
trimer
crystal
class
ii
ectodomain
roughli
show
path
miss
stem
region
complet
protein
hairpin
adapt
permiss
schemat
represent
doublelay
helic
rod
structur
one
three
chain
trimer
depict
inner
layer
rod
form
three
copi
segment
blue
outer
layer
organ
betastrand
residu
alphahelic
residu
red
green
arrow
repres
fusion
peptid
transmembran
anchor
respect
b
schemat
represent
model
metast
structur
hiv
glycoprotein
rectangl
repres
alphahelic
one
three
chain
trimer
depict
disulphid
bond
shown
dash
green
line
fusion
peptid
insert
caviti
trimer
structur
heptadrepeathel
region
unstructur
dash
yellow
line
tether
transmembran
anchor
green
arrow
adapt
permiss
virus
class
fusion
protein
share
common
mechan
fusion
mediat
glycoprotein
contain
two
hydrophob
heptad
repeat
extracellular
domain
central
complex
conform
chang
lead
fusion
first
heptad
repeat
hrn
adjac
fusion
peptid
second
hrc
immedi
preced
transmembran
domain
figur
fusion
trigger
domain
drastic
rearrang
form
highli
structur
thermodynam
stabl
coiledcoil
three
heptad
repeat
prefus
stalk
conform
intermedi
allow
fusion
peptid
expos
eventu
insert
membran
target
cell
final
stage
membran
fusion
prehairpin
spontan
collaps
postfus
structur
sixhel
bundl
inner
trimer
coil
coil
form
onto
fold
figur
result
membran
merg
format
stabl
fusion
pore
concern
hiv
envelop
protein
arrang
two
non
covalentlylink
glycoprotein
function
attach
function
fusion
form
trimer
spike
project
lipid
viral
envelop
figur
enter
cell
hiv
specif
bind
host
protein
receptor
via
subunit
bind
induc
conform
chang
expos
otherwis
cryptic
bind
site
molecul
one
two
major
hiv
coreceptor
coreceptor
bind
trigger
conform
chang
result
exposur
fusion
peptid
insert
plasma
membran
associ
domain
trimer
form
hairpin
structur
form
thermodynam
stabl
figur
allow
membran
fusion
releas
genom
hiv
directli
cell
cytoplasm
interestingli
cholesterolenrich
lipid
microdomain
plasma
membran
seem
requir
hiv
cell
entri
two
viral
glycoprotein
involv
cell
infect
respiratori
syncyti
viru
rsv
attach
protein
g
fusion
protein
f
protein
bind
heparin
cell
surfac
glycoprotein
allow
attach
howev
process
remain
unclear
interact
g
protein
receptor
thought
initi
conform
chang
f
form
therebi
trigger
membran
fusion
neutral
ph
plasma
membran
ha
hemagglutinin
influenza
viru
anchor
viru
target
cell
attach
sialic
acidrich
receptor
viru
enter
cell
clathrindepend
endocytosi
acid
environ
endosom
low
ph
endosom
activ
ion
channel
bring
proton
across
viral
envelop
result
acidif
viral
interior
ha
trimer
mediat
fusion
viral
endosom
membran
thereaft
acidif
viral
nucleocapsid
allow
genom
releas
host
cell
cytoplasm
convers
class
ii
fusion
protein
mainli
consist
betasheet
fusion
peptid
locat
intern
loop
figur
unlik
class
protein
remain
trimer
conform
rearrang
involv
chang
oligomer
state
prefus
dimer
lie
onto
virion
surfac
postfus
trimer
project
vertic
class
ii
fusion
protein
hallmark
virus
belong
flavivirida
famili
notabl
flaviviru
genu
e
fusion
protein
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
virus
belong
togavirida
famili
particular
protein
alphaviru
semliki
forest
sfv
class
ii
fusion
protein
character
three
globular
domain
compos
almost
entir
betasheet
figur
hing
region
locat
domain
ii
flexibl
zone
allow
differ
angl
two
domain
preand
postfus
conform
fusion
protein
crystal
structur
dengu
viru
e
protein
reveal
pocket
locat
within
hing
region
name
pocket
site
could
accomod
singl
molecul
figur
hydrophob
pocket
import
conform
chang
promot
fusion
thu
block
pocket
impair
flexibl
around
hing
region
could
imped
fusion
reaction
envelop
protein
class
ii
organ
homoor
heterodim
lie
flat
surfac
virion
alphavirus
flavivirus
infect
cell
receptormedi
endocyt
uptak
low
phtrigger
membran
fusion
reaction
fusion
e
protein
flavivirus
protein
alphavirus
form
metast
dimer
viral
surfac
onset
fusion
interact
within
dimer
disrupt
releas
monomer
fusion
protein
lead
exposur
fusion
loop
insert
target
membran
fusion
protein
form
homotrim
requir
fusion
hing
rotat
dramat
rearrang
domain
iii
lead
format
hairpin
fusion
loop
transmembran
domain
end
rodlik
trimer
figur
result
releas
viral
genom
cell
sinc
hcv
member
flavivirida
famili
fusion
protein
assum
belong
class
ii
virion
envelop
bear
two
viral
glycoprotein
current
unknown
render
difficult
studi
hcv
fusion
mechan
molecular
level
howev
model
tertiari
organ
recent
propos
base
upon
identif
disulfid
bond
delin
candid
fusion
loop
furthermor
studi
hcv
cell
entri
larg
hamper
develop
two
function
model
name
hcv
pseudotyp
particl
hcvpp
hcv
grown
cell
cultur
hcvcc
enter
hepatocyt
main
target
cell
product
infect
hcv
bind
set
receptor
coreceptor
includ
low
densiti
lipoprotein
receptor
ldlr
glycosaminoglycan
gag
scaveng
receptor
class
b
type
srbi
tetraspanin
occludin
figur
intern
like
achiev
clathrindepend
endocytosi
follow
low
phdepend
membran
fusion
within
endosom
expect
induc
conform
chang
hcv
releas
hcv
genom
cell
fusion
protein
third
viral
class
class
iii
display
combin
alphahel
betastructur
like
class
protein
form
trimer
prefus
state
contain
central
alphahel
coiledcoil
howev
fusion
region
close
resembl
class
ii
protein
sinc
fusion
peptid
form
loop
expos
tip
extend
betastrand
last
group
includ
fusion
protein
rhabdovirida
g
protein
vesicular
stomat
viru
herpesvirida
gb
herp
simplex
baculovirida
baculoviru
focu
sever
viral
entri
inhibitor
promis
molecul
strategi
alreadi
clinic
summar
tabl
develop
neutral
monoclon
antibodi
mab
promis
antivir
strategi
howev
present
palivizumab
demonstr
clinic
efficaci
licens
us
food
drug
administr
fda
subsequ
differ
world
drug
regulatori
agenc
prevent
sever
rsv
infect
highrisk
children
motavizumab
tabl
novel
recombin
human
mab
develop
palivizumab
motavizumab
possess
enhanc
antirsv
neutral
activ
potent
palivizumab
phase
iii
studi
prevent
rsv
infect
highrisk
children
recent
finish
result
indic
superior
efficaci
motavizumab
compar
palivizumab
popul
patient
histori
prematur
precis
molecular
mechan
action
mab
unknown
howev
bind
rsv
f
protein
recent
studi
demonstr
inhibit
viru
attach
f
protein
interact
cell
membran
viru
bud
howev
antibodi
inhibit
viru
transcript
celltocel
fusion
suggest
could
inhibit
conform
chang
f
protein
therebi
block
fusion
tabl
main
molecul
strategi
alreadi
clinic
exhibit
promis
antivir
activ
hiv
sever
mab
current
investig
ibalizumab
tabl
human
mab
bind
second
domain
receptor
prevent
bind
thought
decreas
flexibl
therebi
hinder
access
phase
studi
ibalizumab
show
promis
activ
resist
emerg
week
administr
phase
ii
studi
ibalizumab
show
mab
combin
antiretrovir
regimen
significantli
reduc
plasma
rna
compar
background
regimen
alon
anoth
interest
mab
block
hiv
cell
entri
target
receptor
efficaci
evalu
phase
ii
clinic
trial
grant
fasttrack
statu
fda
studi
subcutaneouslyadminist
show
potent
antiretrovir
activ
treatment
gener
well
toler
current
phase
ii
clinic
test
wwwprogenicscom
concern
hcv
antibodi
direct
studi
vivo
use
chimer
mice
prophylact
treatment
antibodi
complet
protect
upascid
immunodefici
mice
human
liver
challeng
hcv
consensu
strain
differ
genotyp
author
put
forward
concept
clinic
target
hcv
prevent
especi
context
liver
transplant
lt
inde
satur
donor
liver
antibodi
first
day
follow
graft
reperfus
may
prevent
reinfect
recent
monoclon
antibodi
direct
anoth
receptor
hcv
develop
exhibit
effici
inhibit
hcv
infect
cultur
cell
primari
hepatocyt
nanomolar
rang
antibodi
evalu
vitro
perspect
clinic
use
could
prevent
reinfect
graft
lt
furthermor
also
implic
cellcel
transmiss
antibodi
might
restrain
viru
spread
chronic
infect
patient
combin
two
antibodi
ab
xtl
ab
xtl
recogn
differ
epitop
hcv
evalu
ongo
studi
assess
safeti
toler
antivir
activ
increas
singl
multipl
dose
patient
chronic
hcv
infect
tabl
combin
antibodi
character
biochem
vitro
function
vivo
use
hcvtrimera
mous
model
immunodefici
mous
transplant
ex
vivo
hcvinfect
human
liver
fragment
effici
treat
hcv
infect
human
liver
fragment
reduc
mean
viral
load
hcvposit
anim
seem
effici
agent
taken
separ
may
diminish
risk
emerg
escap
mutant
safeti
pharmacokinet
antivir
effect
civacir
immun
globulin
enrich
human
hepat
c
polyclon
antibodi
hcig
studi
patient
undergo
lt
chronic
hepat
c
tabl
phase
ii
proofofconcept
clinic
trial
initi
involv
patient
receiv
mgkg
civacir
trial
progress
liver
fibrosi
studi
biopsi
liver
enzym
hcv
rna
level
analyz
liver
serum
safeti
toler
evalu
howev
result
yet
made
public
recent
studi
reveal
mab
direct
domain
iii
denv
e
protein
potent
neutral
infect
mous
model
lethal
dengu
fever
illustr
strong
potenti
antibodybas
therapi
sever
form
ill
inhibitor
target
envelop
protein
anoth
approach
inhibit
viru
attach
use
solubl
protein
act
molecular
decoy
therapeut
arsen
hiv
recombin
solubl
form
bind
test
howev
activ
clinic
trial
disappoint
tetraval
fusion
protein
incorpor
four
copi
envbind
domain
promis
tabl
reduct
plasma
rna
level
observ
phase
ii
trial
patient
advanc
hiv
diseas
bound
nanomolar
affin
neutral
regardless
genotyp
also
well
toler
small
molecul
azaindol
deriv
also
inhibit
interact
hiv
one
display
nanomolar
activ
independ
hiv
coreceptor
use
cytotox
pharmacokinet
paramet
analyz
rat
dog
monkey
result
safe
profil
attract
pharmaceut
properti
use
resist
virus
wang
et
al
identifi
mutat
locat
pocket
interact
suggest
molecul
could
interfer
interact
guo
et
al
confirm
hypothesi
show
direct
interact
thu
could
inhibit
bind
protein
via
specif
competit
mechan
eb
peptid
entri
blocker
develop
jone
et
al
influenza
virus
exhibit
broadspectrum
antivir
activ
peptid
induc
signific
cytotox
exhibit
low
rang
furthermor
protect
activ
eb
demonstr
vivo
mice
author
suggest
eb
may
lead
conform
chang
ha
decreas
affin
sialic
acid
receptor
cell
surfac
altern
eb
may
interact
near
receptor
block
site
caus
steric
hindranc
hareceptor
dock
eb
may
also
induc
aggreg
virion
result
decreas
cell
bind
recent
rajik
et
al
describ
smaller
peptid
residu
bind
ha
prevent
cell
attach
influenza
viru
peptid
possess
good
antivir
activ
vitro
ovo
case
hcv
variou
antivir
protein
small
molecul
mention
lectin
cyanovirinn
cvn
protein
isol
aqueou
extract
cyanobacterium
nostoc
ellipsosporum
author
demonstr
cvn
inhibit
cell
entri
low
nanomolar
concentr
cvn
target
glycan
hcv
envelop
protein
block
interact
therebi
prevent
viral
entri
target
cell
protein
initi
discov
base
potent
activ
hiv
inde
boyd
et
al
observ
antihiv
activ
nanomolar
rang
measur
direct
interact
cvn
hiv
lead
viral
membran
fusion
inhibit
moreov
cvn
also
inhibit
sever
strain
influenza
virus
sinc
variou
envelop
protein
virus
glycosyl
approach
could
promis
develop
viral
entri
inhibitor
actinohivin
ah
protein
isol
actinomycet
bind
highmanos
type
sugar
chain
inhibit
hiv
entri
three
segment
ah
within
segment
sever
residu
essenti
activ
cooper
involv
segment
ah
increas
interact
interestingli
ah
endow
broadli
neutral
activ
laboratoryadapt
hiv
strain
varieti
andor
clinic
clade
isol
carbohydratebind
agent
plant
lectin
antibiot
pradimicin
specif
inhibit
hcv
hiv
entri
submicromolar
plant
lectin
micromolar
pradimicin
along
similar
line
solubl
chondroitin
sulphat
e
cse
shown
inhibit
denv
infect
well
viru
bind
host
cell
interact
e
protein
recent
cellular
partner
within
tetraspanin
web
express
sever
cell
type
hepatocyt
describ
modul
hcv
cell
entri
inde
ectop
express
hcvpermiss
hepatoma
cell
line
inhibit
viral
entri
block
hcv
bind
like
interact
howev
molecular
mechan
inhibit
hcv
entri
still
unknown
may
reduc
access
hcv
steric
hindranc
associ
may
induc
conform
rearrang
render
less
access
hcv
interact
altern
may
interfer
actin
polymer
viral
entri
block
signal
pathway
necessari
viral
entri
applic
therapi
sinc
fulllength
protein
could
use
templat
design
smaller
molecul
mimick
antivir
activ
molecul
terfenadin
deriv
could
inhibit
hcv
interact
cyclic
molecul
develop
interact
larg
extracellular
loop
lel
compet
hcv
bind
terfenadin
display
moder
hcv
inhibit
inhibit
interact
deriv
inhibit
interact
concentr
molecul
test
concentr
rang
hcvcc
infect
assay
display
good
inhibitori
effect
sinc
similar
inhibit
obtain
compound
reduc
infect
devoid
activ
proteinprotein
interact
assay
author
specul
molecul
could
interact
addit
target
involv
viral
infect
develop
antivir
molecul
direct
viral
envelop
protein
base
critic
role
protein
play
viral
entri
furthermor
molecul
act
cellular
factor
may
display
moder
low
toxic
convers
type
inhibitor
could
induc
viral
resist
due
select
pressur
viru
lead
mutat
viral
protein
sequenc
molecul
stabil
viral
envelop
protein
alter
conform
therebi
block
oligomer
conform
chang
requir
fusion
type
strategi
appli
rsv
entri
inhibit
two
small
benzimidazol
deriv
develop
interact
rsv
f
fusion
protein
oral
activ
drug
efficaci
nanomolar
rang
cianci
et
al
use
photoaffin
analogu
order
directli
probe
site
interact
inhibitor
fusion
protein
tyrosin
residu
map
within
hydrophob
caviti
thu
could
block
interact
two
heptad
repeat
could
thu
interfer
format
consolid
key
structur
within
hairpin
essenti
membran
fusion
class
fusion
protein
share
common
mechan
action
develop
molecul
promis
act
similar
mechan
could
inhibit
fusion
caus
local
perturb
nativ
conform
rather
block
format
influenza
viru
sensit
class
n
carboxamid
molecul
act
ic
rang
cytotox
howev
molecul
effici
influenza
virus
b
virus
author
report
compound
name
one
potent
molecul
class
inhibit
hamedi
membran
fusion
prevent
ha
conform
chang
low
ph
silico
dock
approach
predict
posit
potenti
bind
pocket
ha
trimer
involv
arginin
glutam
acid
residu
molecul
use
laboratori
tool
design
compound
improv
antivir
effect
broader
spectrum
way
russel
et
al
identifi
hydrophob
pocket
ha
monom
potenti
target
antivir
drug
inde
inhibitor
membran
fusion
tertbutylhydroquinon
shown
occupi
site
stabil
neutral
ph
structur
intersubunit
intrasubunit
interact
presum
inhibit
conform
rearrang
requir
membran
fusion
discoveri
pocket
inhibitori
site
could
lead
develop
potenti
antiinfluenza
drug
cyclic
molecul
target
pocket
dengu
e
fusion
protein
describ
harrison
cowork
locat
nearbi
flexibl
hing
region
figur
could
inhibit
viru
entri
inde
compound
target
hydrophob
pocket
thought
interfer
conform
chang
envelop
protein
essenti
fusion
sever
team
use
silico
screen
discov
inhibitor
target
pocket
activ
denv
yfv
wnv
jev
immunofluoresc
studi
indic
presenc
one
compound
denv
block
endosom
receptormedi
endocytosi
due
alter
endosom
ph
precis
mode
action
remain
determin
author
show
molecul
could
specif
bind
denv
comput
chemistri
reveal
posit
compound
deepli
buri
pocket
therefor
pocket
e
protein
could
promis
target
antivir
e
protein
flavivirus
could
also
target
antivir
peptid
protein
stem
protein
hrobowski
et
al
identifi
peptid
deriv
e
protein
inhibit
wnv
denv
infect
residu
correspond
stem
domain
denv
inhibit
denv
wnv
entri
residu
correspond
wnv
e
domain
iib
inhibit
wnv
denv
infect
mode
action
peptid
appear
sequencespecif
exact
mechan
remain
unclear
may
interfer
interact
stem
portion
viral
fusion
protein
inhibit
interfer
target
cell
surfac
compon
rule
howev
domain
encompass
peptid
iib
preanchor
stem
like
involv
structur
rearrang
within
fusion
protein
fusion
process
rather
direct
interact
cellular
receptor
studi
could
lead
develop
peptidomimet
molecul
would
use
mode
action
recent
schmidt
et
al
identifi
peptid
deriv
stem
region
dengu
e
peptid
bind
trimer
postfus
conform
prefus
dimer
inhibit
infect
block
viral
fusion
recombin
protein
correspond
domain
iii
either
alphaviru
protein
flaviviru
e
protein
inhibit
alphaor
flaviviru
infect
protein
could
interfer
protein
rearrang
fusion
could
block
viru
attach
although
unlik
use
antivir
strong
inhibitori
activ
import
implic
develop
clinic
use
inhibitor
fusion
reaction
brought
class
ii
protein
class
molecul
act
direct
bind
viral
envelop
protein
amphipath
polym
dna
phosphorothio
oligonucleotid
pson
recent
emerg
attract
option
vaillant
et
al
analyz
activ
hiv
infect
polym
inhibitori
activ
depend
amphipath
properti
size
sequenceindepend
importantli
phosphorothio
group
play
essenti
role
increas
overal
hydrophob
pson
block
entri
cell
fusion
assay
lower
nm
due
hydrophob
pson
could
interact
non
specif
hydrophob
molecul
serum
protein
could
affect
vivo
efficaci
activ
pson
hcv
infect
also
test
matsumura
et
al
pson
shown
potent
inhibit
hcv
infect
submicromolar
concentr
similarli
activ
hcv
pseudoparticl
variou
genotyp
pson
also
inhibit
hcv
infect
vivo
chimer
mous
infect
hcv
patient
serum
howev
sinc
hcv
fusion
like
achiev
class
ii
fusion
protein
mechan
action
hiv
hcv
may
conserv
remain
determin
hcv
infect
clinic
evalu
start
test
pson
rep
hcvhbv
coinfect
patient
tabl
current
perform
southeast
asia
evalu
safeti
antivir
efficaci
http
case
hcv
develop
molecul
target
specif
conform
region
one
envelop
protein
sever
hamper
lack
structur
protein
lack
hcv
model
recent
recent
identifi
librari
small
molecul
activ
genotyp
hcv
median
valu
nm
respect
infect
inhibit
cellfre
celltocel
entri
experi
resist
virus
suggest
could
act
envelop
glycoprotein
target
cellular
receptor
could
constitut
good
strategi
sinc
could
limit
mutat
resist
reduc
viral
escap
nevertheless
strategi
may
delic
target
host
protein
play
cellular
role
hiv
sever
molecul
target
cellular
receptor
current
clinic
trial
alreadi
use
clinic
exampl
maraviroc
vicriviroc
two
small
molecul
antagonist
result
two
phase
iii
clinic
trial
studi
vicriviroc
indic
lack
efficaci
lead
merck
termin
develop
programm
juli
http
anewmerckreview
membran
protein
seven
transmembran
domain
tmd
maraviroc
shown
interact
tyrosin
residu
third
tmd
glutam
residu
seventh
tmd
transmembran
pocket
nearbi
distinct
extracellular
domain
recogn
maraviroc
therefor
alter
conform
specif
locat
ectodomain
hiv
bind
tabl
vitro
studi
show
abl
inhibit
entri
panel
clinic
hiv
isol
ic
nanomolar
rang
howev
sinc
target
inhibit
entri
hiv
strain
use
maraviroc
develop
pfizer
sandwich
laboratori
clinic
use
per
os
treatment
infect
pharmacokinet
studi
demonstr
good
oral
bioavail
safeti
toler
although
efficaci
global
good
virolog
failur
observ
howev
virus
highli
resist
maraviroc
remain
sensit
antagonist
could
due
fact
antagonist
would
occupi
exactli
site
select
distinct
conform
bound
receptor
antagonist
develop
studi
aplaviroc
discontinu
report
hepatotox
tabl
antagonist
studi
potent
antivir
vitro
develop
program
termin
inde
patient
signific
level
circul
viru
use
therefor
inhibit
might
argu
coadministr
combin
antagonist
anoth
strategi
interfer
hiv
receptor
could
downregul
express
rapamycin
macrolid
antibiot
alreadi
clinic
use
prophylact
treatment
renal
graft
reject
drug
decreas
express
normal
cell
macrophag
inhibit
vitro
replic
strain
use
gilliam
et
al
test
molecul
express
macaqu
regimen
well
toler
author
observ
reduct
level
mrna
nicoletti
et
al
analyz
effect
rapamycin
chimer
mous
infect
hiv
use
expect
observ
decreas
hiv
rna
level
blood
treat
mice
although
data
suggest
rapamycin
would
mainli
act
hiv
infect
inhibit
express
possibl
effect
well
might
contribut
antivir
activ
might
use
combin
antagonist
reduc
dose
latter
increas
antivir
activ
along
line
two
inhibitor
influenza
viru
develop
base
concept
decreas
receptor
sialic
acid
access
among
clarithromycin
macrolid
antibiot
use
treat
pharyng
tonsil
could
inhibit
two
step
influenza
viru
entri
process
tabl
clarithromycin
reduc
express
sialic
acid
residu
surfac
airway
epitheli
cell
therebi
lower
viru
bind
capac
also
shown
decreas
number
acid
endosom
cell
inhibit
endosom
escap
clarithromycin
decreas
viral
titer
rna
influenza
viru
concentrationdepend
way
efficaci
micromolar
rang
maxim
inhibitori
effect
obtain
inhibitor
name
fludas
tabl
also
reduc
presenc
sialic
acid
cell
surfac
recombin
fusion
protein
compos
sialidas
neuraminidas
catalyt
domain
deriv
actinomyc
viscosu
fuse
cellsurfaceanchor
sequenc
show
potent
antivir
cellprotect
efficaci
panel
laboratori
strain
clinic
isol
influenza
b
virus
inhibit
viru
replic
lower
nanomolar
also
effici
prevent
treat
influenza
infect
mice
administ
aerosol
remov
sialic
acid
airway
epithelium
studi
malakhov
et
al
demonstr
cleav
sialic
acid
use
human
avian
influenza
virus
indic
cell
surfac
sialic
acid
remov
afford
cell
protect
influenza
viru
furthermor
show
vitro
efficaci
clinic
isol
resist
neuraminidas
inhibitor
oseltamivir
thu
may
offer
promis
therapeut
option
season
pandem
influenza
virus
resist
current
avail
antivir
drug
present
phase
ii
clinic
trial
recruit
subject
influenzalik
ill
test
safeti
efficaci
hcv
two
inhibitor
molecul
target
srbi
receptor
develop
current
clinic
trial
tabl
oral
bioavail
inhibit
infect
hcv
genotyp
ec
around
nm
current
phase
clinic
studi
antivir
strategi
target
hcv
receptor
still
limit
new
hcv
receptor
recent
discov
occludin
role
interact
hcv
well
character
yet
anoth
strategi
target
host
proteas
involv
matur
viral
envelop
protein
thu
small
oxocarbaz
molecul
inhibit
human
cathepsin
l
inhibit
cell
entri
sar
sever
acut
respiratori
syndrom
coronaviru
ebola
pseudotyp
viru
nm
process
glycoprotein
precursor
gpc
arenavirus
cellular
proprotein
convertas
site
proteas
crucial
celltocel
propag
infect
thu
rojek
et
al
develop
peptidebas
inhibitor
decrrllcmk
block
celltocel
propag
infect
lymphocyt
choriomening
viru
lcmv
concern
influenza
viru
posttransl
proteolyt
cleavag
prerequisit
viral
entri
host
cell
membran
fusion
activ
least
seven
differ
cellular
trypsintyp
proteas
hat
human
airway
trypsinlik
proteas
could
involv
cleavag
suggest
strategi
target
proteas
could
therefor
great
antiflu
potenti
membran
lipid
composit
play
essenti
role
viral
entri
particular
fusion
step
therefor
target
viru
andor
cell
membran
could
reveal
promis
samaritan
pharmaceut
inc
discov
molecul
unknown
structur
due
patent
protect
tabl
reduc
intracellular
cholesterol
block
organ
lipid
raft
cellular
membran
ultim
prevent
hiv
fusion
http
wwwsamaritanpharmacom
http
significantli
lower
amount
hiv
blood
favor
safeti
profil
minim
side
effect
well
toler
moreov
cell
cultur
assay
demonstr
compar
greater
efficaci
current
approv
antihiv
drug
prevent
hiv
viru
replic
low
toxic
toward
human
cultur
cell
two
random
phase
ii
doubleblind
clinic
trial
aim
test
safeti
efficaci
administ
oral
monotherapi
treatment
hivinfect
patient
http
clinicaltrialsgov
identifi
use
peptid
librari
cheng
et
al
found
novel
broadspectrum
inhibitor
viral
entri
peptid
compos
residu
ntermin
membran
anchor
domain
hcv
protein
inhibit
entri
sever
virus
includ
hcv
wnv
denv
hiv
ineffici
influenza
viru
hbv
activ
peptid
also
studi
context
hiv
infect
direct
virocid
effect
observ
submicromolar
concentr
vitro
suggest
could
permeabil
viral
phospholipid
bilay
interestingli
peptid
seem
mere
act
viral
envelop
cell
membran
prevent
suppress
hcv
infect
vitro
display
favor
profil
vivo
low
toxic
administ
intraven
mice
amphipath
structur
necessari
suffici
virocid
activ
activ
depend
amino
acid
composit
primari
sequenc
howev
due
propens
interact
lipid
membran
may
interact
sever
hydrophob
molecul
therebi
interf
host
metabol
furthermor
peptid
must
administ
intraven
might
difficult
bear
patient
could
limit
bioavail
due
interact
serum
protein
like
fuse
bilay
viral
envelop
local
adopt
hourglassshap
stalk
initi
stage
fusion
process
requir
local
neg
membran
curvatur
st
vincent
et
al
identifi
famili
synthet
rigid
amphiphil
rafi
rigid
amphipath
fusion
inhibitor
nucleosid
deriv
inhibit
infect
hcv
herp
simplex
viru
hsv
interf
neg
curvatur
requir
initi
stage
fusion
similarli
wolf
et
al
identifi
antivir
small
molecul
activ
influenza
flavivirus
specif
intercal
viral
membran
irrevers
inactiv
virion
leav
function
intact
envelop
protein
inhibit
viral
entri
step
viru
bind
viruscel
fusion
membran
consid
concentr
small
molecul
pharmacolog
activ
case
antivir
concentr
could
potenti
antivir
properti
establish
enfuvirtid
dp
peptid
fusion
inhibitor
use
act
way
tabl
enfuvirtid
enf
first
fusion
inhibitor
approv
clinic
use
hiv
infect
becam
avail
acid
peptid
correspond
amino
acid
residu
viral
glycoprotein
enf
bind
intermedi
stage
fusion
first
heptadrepeat
aa
block
interact
competit
bind
hydrophob
groov
trimer
block
format
hairpin
structur
subsequ
fusion
reaction
sever
studi
also
demonstr
inhibitori
effect
enf
could
explain
membran
interact
inde
presenc
three
non
consecut
tryptophan
one
tyrosin
one
phenylalanin
enf
sequenc
suggest
could
interact
interfaci
membran
enf
inde
shown
bind
concentr
oligomer
within
membran
interfac
cell
membran
therefor
play
role
reservoir
enf
local
concentr
molecul
thu
membran
act
catalyst
bind
reaction
peptid
sinc
mechan
action
enf
differ
class
antihiv
medic
effect
patient
fail
therapi
due
emerg
resist
viru
therapeut
use
enf
associ
antihiv
agent
administ
subcutan
inject
twice
daili
dose
mg
drug
minim
system
toxic
frequent
occurr
pain
inject
site
reaction
limit
longterm
use
recent
peptid
inhibitor
hiv
tag
cholesterol
molecul
develop
ingallinella
et
al
order
increas
peptid
efficaci
enhanc
membran
associ
enf
share
common
sequenc
residu
without
cholesteroltag
inhibit
hiv
entri
bind
prehairpin
intermedi
prevent
transit
structur
show
dramat
increas
antivir
potenc
valu
lower
pm
vs
pm
respect
addit
cholesterol
group
could
therefor
creat
specif
enrich
inhibitor
peptid
lipid
microdomain
hivcel
fusion
occur
moreov
derivat
cholesterol
extend
halflif
peptid
vivo
peptid
deriv
region
f
protein
paramyxovirus
inhibit
infect
homolog
virus
porotto
et
al
demonstr
addit
cholesterol
tag
onto
peptid
increas
antivir
potenc
two
log
inde
ic
nm
wherea
approxim
higher
untag
version
peptid
thu
author
suggest
cholesterol
tag
help
increas
rate
inhibitor
associ
prehairpin
intermedi
via
preconcentr
membran
hbv
life
cycl
synthesi
envelop
protein
l
domain
myristoyl
transloc
endoplasm
reticulum
er
modif
essenti
infect
interestingli
peptid
deriv
domain
l
envelop
protein
hbv
exhibit
stronger
antivir
activ
peptid
tag
myristoyl
moieti
preincub
primari
tupaia
hepatocyt
use
model
hbv
infect
myristoyltag
version
aa
complet
inhibit
hbv
infect
nm
wherea
untag
version
necessari
complet
infect
inhibit
interestingli
replac
myrist
acid
fatti
acid
result
chang
inhibitori
activ
notabl
decreas
ic
picomolar
concentr
longer
unbranch
fatti
acid
stearic
acid
presenc
peptid
viral
particl
bind
tupaia
hepatocyt
could
suggest
specif
bind
peptid
cellular
receptor
necessari
hbv
attach
hepatocyt
although
addit
interact
viral
protein
exclud
may
contribut
inhibitori
effect
interact
lipopeptid
put
receptor
molecul
probabl
enhanc
anchorag
hydrophob
myristoyl
moieti
membran
near
futur
hbv
presderiv
lipopeptid
could
administ
prevent
hbv
infect
postexposur
prophylaxi
avoid
reinfect
liver
graft
transplant
hbvinfect
individu
studi
need
evalu
inhibitor
may
play
benefici
role
chronicallyinfect
patient
lipophil
drug
target
cellular
receptor
also
develop
influenza
viru
infect
prior
membran
fusion
low
ph
endosom
activ
influenza
viru
proton
channel
conduct
proton
across
viral
envelop
result
acidif
viral
particl
lumen
promot
viru
uncoat
within
endosom
channel
target
lipophil
adamantan
tricyclodecan
deriv
amantadin
rimantadin
differ
ethylamin
moieti
posit
tabl
amantadin
one
studi
inhibitor
influenza
viru
proton
channel
spite
sever
side
effect
amantadin
use
antiinfluenza
drug
clinic
sinc
also
parkinson
diseas
sinc
deriv
compound
rimantadin
approv
well
amantadin
reach
channel
partit
membran
inde
sever
experi
suggest
amantadin
significantli
solubl
lipid
bilay
aqueou
solut
adopt
preferenti
interfaci
locat
unfortun
rate
onset
viru
resist
drug
global
increas
overlap
crossresist
amantadin
rimantadin
observ
monitor
emerg
spread
resist
virus
therefor
urgent
need
order
appli
appropri
treatment
patient
arbidol
arb
broadspectrum
antivir
demonstr
activ
number
envelop
nonenvelop
virus
initi
use
prophylaxi
treatment
infect
influenza
b
virus
arb
small
indolederiv
molecul
first
market
russia
china
gener
administ
oral
mg
time
day
day
flu
given
mg
dose
day
day
prophylaxi
subject
contact
symptomat
patient
treatment
shown
reduc
durat
ill
day
infect
patient
prevent
develop
postinfluenza
complic
furthermor
therapeut
efficaci
arb
pronounc
drug
administ
earli
infect
although
arb
clinic
use
year
arbresist
virus
isol
far
major
advantag
arb
adamantan
clinic
trial
conduct
patient
year
experi
arb
russia
reveal
arb
well
toler
minor
side
effect
arb
entri
inhibitor
precis
fusion
inhibitor
mechanist
arb
inhibit
influenza
virusinduc
membran
fusion
immunomodulatori
effect
report
arb
interact
influenza
ha
stabil
prevent
low
phinduc
conform
chang
lead
membran
fusion
stabil
consequ
lead
inhibit
endosom
membran
fusion
recent
antivir
action
hcv
demonstr
acut
chronic
hcv
infect
arb
inhibit
hcv
membran
fusion
cell
infect
variou
genotyp
et
al
alreadi
shown
arb
could
interact
micel
membran
variou
composit
recent
work
arb
locat
membran
studi
arb
shown
mainli
interact
polar
headgroup
phospholipid
membran
interfac
appar
affin
low
micromolar
rang
indic
least
part
arb
inhibitori
activ
could
explain
membranotrop
interact
phospholipid
would
local
perturb
membran
fluiditi
key
paramet
fusion
process
therebi
render
lipid
bilay
less
prone
fusion
moreov
indol
structur
allow
interact
aromat
residu
tryptophan
inde
show
direct
interact
arb
tryptophan
residu
variou
membranotrop
peptid
membran
environ
appar
affin
rang
interestingli
appar
bind
affin
lipid
tryptophan
residu
rang
ic
hcv
membran
fusion
sinc
tryptophan
residu
membran
protein
known
bind
preferenti
membran
interfac
data
suggest
arb
could
increas
strength
hcv
glycoprotein
interact
membran
due
dual
bind
mode
involv
aromat
residu
phospholipid
result
complex
would
reduc
overal
speed
fusion
reaction
rather
block
specif
protein
conform
lead
inhibit
expect
hcv
glycoprotein
conform
chang
requir
membran
fusion
process
arb
safeti
demonstr
influenza
infect
togeth
vitro
efficaci
hcv
suggest
arb
could
good
antihcv
drug
candid
coadministr
antivir
molecul
hcv
treatment
could
help
improv
efficaci
andor
reduc
dose
current
treatment
part
detail
antivir
agent
direct
hcv
entri
precis
target
unknown
polypeptid
contain
portion
transmembran
domain
shown
inhibit
cell
entri
hcv
pseudoparticl
approxim
nm
effect
vsv
hiv
pseudoparticl
entri
suggest
specif
action
hcv
antivir
activ
depend
upon
lconfigur
amino
acid
overal
hydrophob
charact
peptid
hydrophob
charact
suffici
sinc
nativ
sequenc
requir
optim
activ
peptid
exhibit
direct
virocid
activ
hcv
pseudoparticl
act
postbind
step
sever
plant
extract
recent
shown
block
hcv
entri
antivir
iridoid
isom
lamiridosin
b
extract
flower
top
lamium
album
inhibit
hcv
entri
vitro
ic
rang
sinc
activ
vsv
entri
author
suggest
drug
could
select
hcv
exact
mechan
action
identifi
yet
least
interfer
interact
could
rule
silymarin
sm
anoth
plant
extract
obtain
seed
milk
thistl
silybum
marianum
tabl
extract
contain
multipl
flavonolignan
includ
silybin
racem
mixtur
diastereoisom
b
isosilybin
b
silychristin
silydianin
phenol
compound
sm
use
centuri
hepat
disord
hepatoprotect
role
known
hundr
year
thought
antioxid
antiinflammatori
immunomodulatori
antitumor
effect
moreov
sm
display
major
side
effect
current
milk
thistl
extract
market
worldwid
includ
unit
state
capsuletablet
silymarin
silibinin
enhanc
bioavail
variou
trade
name
silipho
silipid
legalon
survey
indic
person
chronic
hepat
c
chc
often
use
herbal
especi
sm
hope
improv
modest
respons
certain
antivir
therapi
reduc
side
effect
use
potenti
effect
sm
studi
trial
involv
patient
advanc
chc
nonrespond
prior
therapi
studi
conclud
user
sm
similar
alanin
aminotransferas
hcv
level
nonus
exhibit
fewer
symptom
somewhat
better
qualiti
life
clinic
trial
test
efficaci
safeti
sm
program
current
recruit
hcvinfect
patient
http
clinicaltrialsgov
identifi
clinic
trial
studi
safeti
efficaci
silibinin
major
compon
silymarin
hcvinfect
patient
nonrespond
pegylatedifnribavirin
pegifnrbv
studi
substanti
antivir
effect
hcv
nonrespond
observ
dosedepend
reduct
viral
load
week
combin
silibinin
pegifnrbv
therapi
recent
success
suppress
earli
hcv
reinfect
liver
transplant
cours
silibinin
monotherapi
report
sever
articl
recent
show
action
sm
compon
variou
stage
hcv
infect
howev
mechan
action
remain
unclear
sm
differ
compon
exhibit
inhibit
hcvcc
infect
ic
observ
inhibit
hcv
entri
sm
interfer
viruscel
bind
suggest
inhibit
could
occur
postbind
stage
use
lipid
mix
fusion
assay
demonstr
sm
inhibit
membran
fusion
ic
around
thu
reinforc
notion
sm
could
inhibit
hcv
entri
fusion
stage
recent
studi
compar
antivir
effect
silibinin
insolubl
aqueou
solut
oral
administ
intraven
formul
legalonsil
wagon
et
al
revis
legalonsil
differ
silibinin
two
succin
moieti
coval
attach
diastereoisom
interestingli
legalonsil
display
much
potent
inhibitori
effect
hcv
fusion
silibinin
ic
vs
ca
respect
therefor
suggest
due
phenylbenzopyron
chemic
structur
therebi
hydrophob
sm
compon
could
act
incorpor
lipid
membran
could
lead
stabil
membran
would
turn
becom
less
prone
fusion
spite
resist
issu
success
develop
regulatori
approv
enfuvirtid
maraviroc
amantadin
shown
viral
entri
valid
target
therapeut
intervent
seem
obviou
near
futur
effect
treatment
hcv
envelop
virus
becom
avail
possibl
includ
optim
small
molecul
antivir
agent
peptid
protein
nucleic
acidbas
therapi
inhibitor
target
variou
step
viru
cell
entri
viral
cellular
compon
sinc
host
viral
target
proven
valid
antivir
develop
interestingli
inhibitor
concentr
intoonto
membran
order
target
protein
involv
entri
process
arbidol
hiv
peptid
inhibitor
could
allow
use
dose
compat
therapeut
requir
gener
discoveri
molecul
block
sever
step
viral
life
cycl
could
lead
combin
therapi
also
permit
lower
respect
dose
molecul
consequ
resist
side
effect
issu
